Exciting news from FACCNE member Nanobiotix, a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer: Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer. The data was presented at the 2019 AACR Annual Meeting.
